Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication

Experimental Parasitology

Volumn 128, Issue 2, 2011, Pages 170-175

  Brumlik, Michael J ^a   Nkhoma, Standwell ^b   Kious, Mark J ^a   Thompson, George R ^c,d   Patterson, Thomas F ^c,e   Siekierka, John J ^f   Anderson, Tim J C ^b   Curiel, Tyler J ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^f MONTCLAIR STATE UNIVERSITY   (United States)

Author keywords

Indole 5 carboxamide; Mitogen activated protein kinase; Plasmodium falciparum; Pyridinylimidazole; Pyrrolobenzimidazole

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; CHLOROQUINE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; RWJ 68198; UNCLASSIFIED DRUG;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ANTIPROTOZOAL ACTIVITY; APICOMPLEXAN LIFE CYCLE STAGE; ARTICLE; CONTROLLED STUDY; DIFFERENTIATION; ERYTHROCYTE; EX VIVO STUDY; HUMAN; HUMAN CELL; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; STRAIN DIFFERENCE; TROPHOZOITE;

ANTIMALARIALS; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; HUMANS; IMIDAZOLES; INDOLES; INHIBITORY CONCENTRATION 50; MEFLOQUINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMODIUM FALCIPARUM; PROTEIN KINASE INHIBITORS; PYRIDINES;

ENCEPHALITOZOON CUNICULI; PLASMODIUM FALCIPARUM; PROTOZOA; TOXOPLASMA GONDII;

EID: 79954419998     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.02.016     Document Type: Article

References (29)

1. Bhasin V.K., Trager W. Gametocyte-forming and non-gametocyte-forming clones of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 1984, 33:534-537.
2. Biftu T., Feng D., Ponpipom M., Girotra N., Liang G.B., Qian X., Bugianesi R., Simeone J., Chang L., Gurnett A., Liberator P., Dulski P., Leavitt P.S., Crumley T., Misura A., Murphy T., Rattray S., Samaras S., Tamas T., Mathew J., Brown C., Thompson D., Schmatz D., Fisher M., Wyvratt M. Synthesis and SAR of 2,3-diarylpyrrole inhibitors of parasite cGMP-dependent protein kinase as novel anticoccidial agents. Bioorganic and Medicinal Chemistry Letters 2005, 15:3296-3301.
3. Brumlik, M.J., Pandeswara, S., Ludwig, S.M., Murthi, K., Curiel, T.J. 2011. Parasite mitogen-activated protein kinases as drug discovery targets to treat human protozoan pathogens. Journal of Signal Transduction 2011, Article ID 971968, (16pp).
4. Brumlik M.J., Wei S., Finstad K., Nesbit J., Hyman L.E., Lacey M., Burow M.E., Curiel T.J. Identification of a novel mitogen-activated protein kinase in Toxoplasma gondii. International Journal for Parasitology 2004, 34:1245-1254.
5. Chaturvedi D., Goswami A., Saikia P.P., Barua N.C., Rao P.G. Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chemical Society Reviews 2009, 39:435-454.
6. Dodd, J.H., Henry, J.R., Rupert, K.C. 2000. Substituted pyrrolobenzimidazoles for treating inflammatory diseases. 2000. Patent 6147,096.
7. Dorin-Semblat D., Quashie N., Halbert J., Sicard A., Doerig C., Peat E., Ranford-Cartwright L., Doerig C. Functional characterization of both MAP kinases of the human malaria parasite Plasmodium falciparum by reverse genetics. Molecular Microbiology 2007, 65:1170-1180.
8. Dorin D., Le Roch K., Sallicandro P., Alano P., Parzy D., Poullet P., Meijer L., Doerig C. Pfnek-1, a NIMA-related kinase from the human malaria parasite Plasmodium falciparum Biochemical properties and possible involvement in MAPK regulation. European Journal of Biochemistry 2001, 268:2600-2608.
9. Ekland E.H., Fidock D.A. Advances in understanding the genetic basis of antimalarial drug resistance. Current Opinions in Microbiology 2007, 10:363-370.
10. Gamo F.J., Sanz L.M., Vidal J., de Cozar C., Alvarez E., Lavandera J.L., Vanderwall D.E., Green D.V., Kumar V., Hasan S., Brown J.R., Peishoff C.E., Cardon L.R., Garcia-Bustos J.F. Thousands of chemical starting points for antimalarial lead identification. Nature 2010, 465:305-310.
11. Halawani D., Mondeh R., Stanton L.A., Beier F. p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation. Oncogene 2004, 23:3726-3731.
12. Hammaker D., Firestein G.S. " Go upstream, young man": lessons learned from the p38 saga. Annals of the Rheumatic Diseases 2010, 69(Suppl 1):i77-i82.
13. Johnson J.D., Dennull R.A., Gerena L., Lopez-Sanchez M., Roncal N.E., Waters N.C. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrobial Agents and Chemotherapy 2007, 51:1926-1933.
14. Lacey M.R., Brumlik M.J., Yenni R.E., Burow M.E., Curiel T.J. Toxoplasma gondii expresses two mitogen-activated protein kinase genes that represent distinct protozoan subfamilies. Journal of Molecular Evolution 2007, 64:4-14.
15. Liotta F., Siekierka J.J. Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets. Current Opinion in Investigational Drugs 2010, 11:147-156.
16. Oduola A.M., Milhous W.K., Weatherly N.F., Bowdre J.H., Desjardins R.E. Plasmodium falciparum: induction of resistance to mefloquine in cloned strains by continuous drug exposure in vitro. Experimental Parasitology 1988, 67:354-360.
17. Parsons M., Worthey E.A., Ward P.N., Mottram J.C. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 2005, 6:127.
18. Renslo A.R., McKerrow J.H. Drug discovery and development for neglected parasitic diseases. Nature Chemistry Biology 2006, 2:701-710.
19. Rupert K.C., Henry J.R., Dodd J.H., Wadsworth S.A., Cavender D.E., Olini G.C., Fahmy B., Siekierka J.J. Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorganic and Medicinal Chemistry Letters 2003, 13:347-350.
20. Shapiro L., Heidenreich K.A., Meintzer M.K., Dinarello C.A. Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:7422-7426.
21. Sweitzer S.M., Medicherla S., Almirez R., Dugar S., Chakravarty S., Shumilla J.A., Yeomans D.C., Protter A.A. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 2004, 109:409-419.
22. Tong L., Pav S., White D.M., Rogers S., Crane K.M., Cywin C.L., Brown M.L., Pargellis C.A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Structural Biology 1997, 4:311-316.
23. Trager W., Jensen J.B. Human malaria parasites in continuous culture. Science 1976, 193:673-675.
24. Wadsworth S.A., Cavender D.E., Beers S.A., Lalan P., Schafer P.H., Malloy E.A., Wu W., Fahmy B., Olini G.C., Davis J.E., Pellegrino-Gensey J.L., Wachter M.P., Siekierka J.J. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Journal of Pharmacology and Experimental Therapeutics 1999, 291:680-687.
25. Wei S., Daniel B.J., Brumlik M.J., Burow M.E., Zou W., Khan I.A., Wadsworth S., Siekierka J., Curiel T.J. Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection. Antimicrobial Agents and Chemotherapy 2007, 51:4324-4328.
26. Wei S., Marches F., Daniel B., Sonda S., Heidenreich K., Curiel T. Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. International Journal for Parasitology 2002, 32:969-977.
27. Wiese M. A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host. EMBO Journal 1998, 17:2619-2628.
28. Wiese M. Leishmania MAP kinases-familiar proteins in an unusual context. International Journal for Parasitology 2007, 37:1053-1062.
29. Witkowski B., Berry A., Benoit-Vical F. Resistance to antimalarial compounds: methods and applications. Drug Resistance Updates 2009, 12:42-50.